Page 112 - 《中国药房》2023年4期

[12] OVERMAN M J，LONARDI S，WONG K Y M，et al. Du‐ AtezoTRIBE study by GONO[J]. Ann Oncol，2021，32：
rable clinical benefit with nivolumab plus ipilimumab in S1294-S1295.
DNA mismatch repair-deficient/microsatellite instability- [22] METTU N B，OU F S，ZEMLA T J，et al. Assessment of
high metastatic colorectal cancer[J]. J Clin Oncol，2018， capecitabine and bevacizumab with or without atezoli‐
36（8）：773-779. zumab for the treatment of refractory metastatic colorectal
[13] ANDRÉ T，SHIU K K，KIM T W，et al. Pembrolizumab cancer：a randomized clinical trial[J]. JAMA Netw Open，
in microsatellite-instability-high advanced colorectal can‐ 2022，5（2）：e2149040.
cer[J]. N Engl J Med，2020，383（23）：2207-2218. [23] LE D T，URAM J N，WANG H，et al. PD-1 blockade in
[14] BENSON A B，VENOOK A P，AL-HAWARY M M，et al. tumors with mismatch-repair deficiency[J]. N Engl J Med，
Colon cancer，version 2.2021，NCCN clinical practice 2015，372（26）：2509-2520.
guidelines in oncology[J]. J Natl Compr Canc Netw， [24] BRAHMER J R，TYKODI S S，CHOW L Q，et al. Safety
2021，19（3）：329-359. and activity of anti-PD-L1 antibody in patients with
[15] ENG C，KIM T W，BENDELL J，et al. Atezolizumab with advanced cancer[J]. N Engl J Med，2012，366（26）：2455-
or without cobimetinib versus regorafenib in previously 2465.
treated metastatic colorectal cancer（IMblaze370）：a multi‐ [25] BASILE D，GARATTINI S K，BONOTTO M，et al.
centre，open-label，phase 3，randomised，controlled trial Immunotherapy for colorectal cancer：where are we hea-
[J]. Lancet Oncol，2019，20（6）：849-861. ding?[J]. Expert Opin Biol Ther，2017，17（6）：709-721.
[16] OVERMAN M J，MCDERMOTT R，LEACH J L，et al. [26] SHARMA P，HU-LIESKOVAN S，WARGO J A，et al. Pri‐
Nivolumab in patients with metastatic DNA mismatch mary，adaptive，and acquired resistance to cancer immuno‐
repair-deficient or microsatellite instability-high colorectal therapy[J]. Cell，2017，168（4）：707-723.
cancer（CheckMate 142）：an open-label，multicentre， [27] LE D T，HUBBARD-LUCEY V M，MORSE M A，et al. A
phase 2 study[J]. Lancet Oncol，2017，18（9）：1182-1191. blueprint to advance colorectal cancer immunotherapies
[17] EISENHAUER E A，THERASSE P，BOGAERTS J，et al. [J]. Cancer Immunol Res，2017，5（11）：942-949.
New response evaluation criteria in solid tumours：revised [28] NETWORK C G A. Comprehensive molecular characteri-
RECIST guideline：version 1.1[J]. Eur J Cancer，2009，45 zation of human colon and rectal cancer[J]. Nature，2012，
（2）：228-247. 487（7407）：330-337.
[18] PANIC N，LEONCINI E，DE BELVIS G，et al. Evaluation [29] VOGELSTEIN B，PAPADOPOULOS N，VELCULESCU
of the endorsement of the preferred reporting items for V E，et al. Cancer genome landscapes[J]. Science，2013，
systematic reviews and meta-analysis（PRISMA）state‐ 339（6127）：1546-1558.
ment on the quality of published systematic review and [30] BROWNING M，PETRONZELLI F，BICKNELL D，et al.
meta-analyses[J]. PLoS One，2013，8（12）：e83138. Mechanisms of loss of HLA class Ⅰ expression on colorec‐
[19] GREEN S，HIGGINS J P. Preparing a cochrane review tal tumor cells[J]. Tissue Antigens，1996，47（5）：364-371.
[M]//Cochrane Handbook for Systematic Reviews of Inter‐ [31] GRASSO C S，GIANNAKIS M，WELLS D K，et al.
ventions. Chichester，UK：John Wiley & Sons，Ltd.，2008： Genetic mechanisms of immune evasion in colorectal
11-30. cancer[J]. Cancer Discov，2018，8（6）：730-749.
[20] CHEN E X，JONKER D J，LOREE J M，et al. Effect of [32] PAI S G，CARNEIRO B A，MOTA J M，et al. Wnt/beta-
combined immune checkpoint inhibition vs best suppor- catenin pathway：modulating anticancer immune response
tive care alone in patients with advanced colorectal cancer： [J]. J Hematol Oncol，2017，10（1）：101.
the Canadian cancer trials group CO. 26 study[J]. JAMA [33] LEE J J，CHU E. Recent advances in the clinical develop‐
Oncol，2020，6（6）：831-838. ment of immune checkpoint blockade therapy for mis‐
[21] CREMOLINI C，ROSSINI D，ANTONIOTTI C，et al. match repair proficient（pMMR）/non-MSI-H metastatic
LBA20 FOLFOXIRI plus bevacizumab（bev）plus atezoli‐ colorectal cancer[J]. Clin Colorectal Cancer，2018，17（4）：
zumab（atezo）versus FOLFOXIRI plus bev as first-line 258-273.
treatment of unresectable metastatic colorectal cancer （收稿日期：2022-07-07 修回日期：2023-01-09）
（mCRC）patients：results of the phase Ⅱ randomized （编辑：陈 宏）

· 486 · China Pharmacy 2023 Vol. 34 No. 4 中国药房 2023年第34卷第4期